GlassScriptPhysician profile
Fayez H Hadidi
NPI 1851472716
$2,512.14
in general payments reported to CMS, 2019-2025
21 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $141 · 2021: $331 · 2022: $220 · 2023: $387 · 2024: $1,109 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $319.92 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $303.24 | 2021-2025 | |
| Abbott Laboratories | $255.73 | 2020-2024 | Aveir |
| Merck Sharp & Dohme LLC | $241.35 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $239.11 | 2019-2024 | Xarelto |
| Recor Medical INC | $172.17 | 2024 | Paradise Renal Denervation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.40 | 2024-2025 | Lifevest |
| Pfizer INC. | $133.76 | 2019-2024 | |
| Boston Scientific Corporation | $123.86 | 2023-2025 | Bodyguardian, Watchman Flx |
| Shockwave Medical, INC | $97.45 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $84.32 | 2019-2024 | Farxiga |
| Amgen INC. | $76.65 | 2019-2023 | Repatha |
| Esperion Therapeutics, INC. | $74.63 | 2021-2023 | Nexletol |
| Inspire Medical Systems, INC. | $68.18 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $55.04 | 2019-2025 | Camzyos |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.03 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.30 | 2021 | |
| Novo Nordisk INC | $22.49 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $22.36 | 2024 | Uptravi, Opsumit |
| Venclose INC. | $14.84 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fayez Hadidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.